Galectin 3 regulates HCC cell invasion by RhoA and MLCK activation

Laboratory Investigation

Volumn 95, Issue 10, 2015, Pages 1145-1156

  Serizawa, Nobuko ^a   Tian, Jijing ^a,b   Fukada, Hiroo ^a   Baghy, Kornelia ^a   Scott, Fiona ^a   Chen, Xiangling ^a   Kiss, Zsofia ^a   Olson, Kristin ^a   Hsu, Dan ^a   Liu, Fu Tong ^a   Török, Natalie J ^a   Zhao, Bin ^b   Jiang, Joy X ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b RESEARCH CENTER FOR ECO ENVIRONMENTAL SCIENCES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; GALECTIN 3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYOSIN LIGHT CHAIN 2; MYOSIN LIGHT CHAIN KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SMALL INTERFERING RNA; CARDIAC MYOSIN; LGALS3 PROTEIN, MOUSE; MYOSIN LIGHT CHAIN; PROTEIN KINASE INHIBITOR; RHO KINASE; TUMOR PROTEIN;

ACTIN FILAMENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER SIZE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME ACTIVATION; ENZYME ACTIVITY; HEPATOMA CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; LIVER PARENCHYMA; MALE; METASTASIS; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; TRANSACTIVATION; TUMOR INVASION; UPREGULATION; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CARCINOMA, HEPATOCELLULAR; CELL MOTION; CHEMISTRY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; KNOCKOUT MOUSE; LIVER; LIVER NEOPLASMS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PROTEIN PROCESSING; TUMOR CELL LINE;

ACTIN CYTOSKELETON; ANIMALS; CARCINOMA, HEPATOCELLULAR; CARDIAC MYOSINS; CELL LINE, TUMOR; CELL MOVEMENT; ENZYME ACTIVATION; GALECTIN 3; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; LIVER; LIVER NEOPLASMS; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOSIN LIGHT CHAINS; MYOSIN-LIGHT-CHAIN KINASE; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RHO-ASSOCIATED KINASES; RHOA GTP-BINDING PROTEIN;

EID: 84942815047     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2015.77     Document Type: Article

References (37)

1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-1917.
2. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009;27:1485-1491.
3. Liu FT. Molecular biology of IgE-binding protein, IgE-binding factors, and IgE receptors. Crit Rev Immunol 1990;10:289-306.
4. Newlaczyl AU, Yu LG. Galectin-3-a jack-of-all-trades in cancer. Cancer Lett 2011;313:123-128.
5. Henderson NC, Sethi T. The regulation of inflammation by galectin-3. Immunol Rev 2009;230:160-171.
6. MacKinnon AC, Farnworth SL, Hodkinson PS et al. Regulation of alternative macrophage activation by galectin-3. J Immunol 2008;180: 2650-2658.
7. Henderson NC, Mackinnon AC, Farnworth SL et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci USA 2006;103:5060-5065.
8. Jiang JX, Chen X, Hsu DK et al. Galectin-3 modulates phagocytosisinduced stellate cell activation and liver fibrosis in vivo. Am J Physiol Gastrointest Liver Physiol 2012;302:G439-G446.
9. Hsu DK, Dowling CA, Jeng KC et al. Galectin-3 expression is induced in cirrhotic liver and hepatocellular carcinoma. Int J Cancer 1999;81: 519-526.
10. Matsuda Y, Yamagiwa Y, Fukushima K et al. Expression of galectin-3 involved in prognosis of patients with hepatocellular carcinoma. Hepatol Res 2008;38:1098-1111.
11. Strik HM, Deininger MH, Frank B et al. Galectin-3: cellular distribution and correlation with WHO-grade in human gliomas. J Neurooncol 2001;53:13-20.
12. Rabinovich GA, Toscano MA, Jackson SS et al. Functions of cell surface galectin-glycoprotein lattices. Curr Opin Struct Biol 2007;17:513-520.
13. Parri M, Chiarugi P. Rac and Rho GTPases in cancer cell motility control. Cell Commun Signal 2010;8:23.
14. Hsu DK, Yang RY, Pan Z et al. Targeted disruption of the galectin-3 gene results in attenuated peritoneal inflammatory responses. Am J Pathol 2000;156:1073-1083.
15. Van Antwerp DJ, Martin SJ, Kafri T et al. Suppression of TNF-alphainduced apoptosis by NF-kappaB. Science 1996;274:787-789.
16. Rubins NE, Friedman JR, Le PP et al. Transcriptional networks in the liver: hepatocyte nuclear factor 6 function is largely independent of Foxa2. Mol Cell Biol 2005;25:7069-7077.
17. Liu FT, Hsu DK, Zuberi RI et al. Expression and function of galectin-3, a beta-galactoside-binding lectin, in human monocytes and macrophages. Am J Pathol 1995;147:1016-1028.
18. He G, Karin M. NF-kappaB and STAT3-key players in liver inflammation and cancer. Cell Res 2011;21:159-168.
19. Hsu DK, Hammes SR, Kuwabara I et al. Human T lymphotropic virus-I infection of human T lymphocytes induces expression of the beta-galactoside-binding lectin, galectin-3. Am J Pathol 1996;148: 1661-1670.
20. Liu L, Sakai T, Sano N et al. Nucling mediates apoptosis by inhibiting expression of galectin-3 through interference with nuclear factor kappaB signalling. Biochem J 2004;380(Pt 1):31-41.
21. Hakuma N, Kinoshita I, Shimizu Y et al. E1AF/PEA3 activates the Rho/ Rho-associated kinase pathway to increase the malignancy potential of non-small-cell lung cancer cells. Cancer Res 2005;65:10776-10782.
22. Matsumura F, Totsukawa G, Yamakita Y et al. Role of myosin light chain phosphorylation in the regulation of cytokinesis. Cell Struct Funct 2001;26:639-644.
23. Caramel J, Quignon F, Delattre O. RhoA-dependent regulation of cell migration by the tumor suppressor hSNF5/INI1. Cancer Res 2008;68: 6154-6161.
24. Wong CC, Wong CM, Au SL et al. RhoGTPases and Rho-effectors in hepatocellular carcinoma metastasis: ROCK N'Rho move it. Liver Int; 30: 642-656.
25. Nangia-Makker P, Balan V, Raz A. Regulation of tumor progression by extracellular galectin-3. Cancer Microenviron 2008;1:43-51.
26. Genda T, Sakamoto M, Ichida T et al. Cell motility mediated by rho and Rho-associated protein kinase plays a critical role in intrahepatic metastasis of human hepatocellular carcinoma. Hepatology 1999;30: 1027-1036.
27. Kahsai AW, Cui J, Kaniskan HU et al. Analogs of tetrahydroisoquinoline natural products that inhibit cell migration and target galectin-3 outside of its carbohydrate-binding site. J Biol Chem 2008;283: 24534-24545.
28. Glinskii OV, Sud S, Mossine VV et al. Inhibition of prostate cancer bone metastasis by synthetic TF antigen mimic/galectin-3 inhibitor lactulose-L-leucine. Neoplasia 2012;14:65-73.
29. Pikarsky E, Porat RM, Stein I et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004;431: 461-466.
30. Haybaeck J, Zeller N, Wolf MJ et al. A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell 2009;16:295-308.
31. Margadant C, van den Bout I, van Boxtel AL et al. Epigenetic regulation of galectin-3 expression by beta1 integrins promotes cell adhesion and migration. J Biol Chem 2012;287:44684-44693.
32. Kastl L, Sauer SW, Ruppert T et al. TNF-alpha mediates mitochondrial uncoupling and enhances ROS-dependent cell migration via NF-kappaB activation in liver cells. FEBS Lett 2014;588:175-183.
33. Li J, Lau G, Chen L et al. Interleukin 23 promotes hepatocellular carcinoma metastasis via NF-kappa B induced matrix metalloproteinase 9 expression. PLoS One 2012;7:e46264.
34. Wu KL, Huang EY, Jhu EW et al. Overexpression of galectin-3 enhances migration of colon cancer cells related to activation of the K-Ras-Raf-Erk1/2 pathway. J Gastroenterol 2013;48:350-359.
35. Shimura T, Takenaka Y, Tsutsumi S et al. Galectin-3, a novel binding partner of beta-catenin. Cancer Res 2004;64:6363-6367.
36. Inohara H, Akahani S, Raz A. Galectin-3 stimulates cell proliferation. Exp Cell Res 1998;245:294-302.
37. Hu Z, Jiang X, Xu Y et al. Downregulation of galectin-3 by EGF mediates the apoptosis of HepG2 cells. Mol Cell Biochem 2012;369:157-165.